Lithium reduces aquaporin-2 transcription independent of prostaglandins

American Journal of Physiology - Cell Physiology

Volumn 302, Issue 1, 2012, Pages

  Kortenoeven, Marleen L A ^a   Schweer, Horst ^b   Cox, Rik ^a   Wetzels, Jack F M ^a   Deen, Peter M T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

AQP2 water channel; mpkCCD cells; Nephrogenic diabetes insipidus; Water transport

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; GLYCOGEN SYNTHASE KINASE 3BETA; INDOMETACIN; LITHIUM; LUCIFERASE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; PROSTANOID RECEPTOR; THROMBOXANE B2; ZINC;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEGRADATION; DOWN REGULATION; DRUG EXCRETION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENETIC TRANSCRIPTION; LYSOSOME; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; WATER ABSORPTION;

ANIMALS; AQUAPORIN 2; CELLS, CULTURED; DOWN-REGULATION; LITHIUM; MICE; PROSTAGLANDINS; TRANSCRIPTION, GENETIC;

EID: 83455208277     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00197.2011     Document Type: Article

References (67)

1. Abassi Z, Brodsky S, Gealekman O, Rubinstein I, Hoffman A, Winaver J. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 280: F43-F53, 2001.
2. Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 149: 1123-1126, 1989.
3. Batlle D, Gaviria M, Grupp M, Arruda JA, Wynn J, Kurtzman NA. Distal nephron function in patients receiving chronic lithium therapy. Kidney Int 21: 477-485, 1982.
4. Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 312: 408-414, 1985.
5. Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 3: 1324-1331, 2008.
6. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol 26: 1366-1373, 1999.
7. Bomalaski JS, Clark MA. Phospholipase A2 and arthritis. Arthritis Rheum 36: 190-198, 1993.
8. Boone M, Kortenoeven ML, Robben JH, Tamma G, Deen PM. Counteracting vasopressin-mediated water reabsorption by ATP, dopamine, and phorbol esters: mechanisms of action. Am J Physiol Renal Physiol 300: F761-F771, 2011.
9. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10: 329-345, 1987.
10. Breyer MD, Breyer RM. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 9: 23-29, 2000.
11. Breyer MD, Zhang Y, Guan YF, Hao CM, Hebert RL, Breyer RM. Regulation of renal function by prostaglandin E receptors. Kidney Int Suppl 67: S88-S94, 1998.
12. Campean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 285: F19-F32, 2003.
13. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 5: 241, 2004.
14. Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 291: F39-F48, 2006.
15. Christensen BM, Marples D, Kim YH, Wang W, Frokiaer J, Nielsen S. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 286: C952-C964, 2004.
16. Christensen BM, Zuber AM, Loffing J, Stehle JC, Deen PM, Rossier BC, Hummler E. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 22: 253-261, 2011.
17. Clement JQ, Qian L, Kaplinsky N, Wilkinson MF. The stability and fate of a spliced intron from vertebrate cells. RNA 5: 206-220, 1999.
18. Deen PMT, Verdijk MAJ, Knoers NVAM, Wieringa B, Monnens LAH, van Os CH, van Oost BA. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264: 92-95, 1994.
19. Farman N, Pradelles P, Bonvalet JP. PGE2, PGF2α, 6-keto-PGF1α, and TxB2 synthesis along the rabbit nephron. Am J Physiol Renal Fluid Electrolyte Physiol 252: F53-F59, 1987.
20. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105: 2052-2057, 2008.
21. Fushimi K, Sasaki S, Marumo F. Phosphorylation of serine 256 is required for cAMP- dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 272: 14800-14804, 1997.
22. Hansen HE, Hestbech J, Sorensen JL, Norgaard K, Heilskov J, Amdisen A. Chronic interstitial nephropathy in patients on long-term lithium treatment. Q J Med 48: 577-591, 1979.
23. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70: 357-377, 2008.
24. Hao CM, Yull F, Blackwell T, Kömhoff M, Davis LS, Breyer MD. Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 106: 973-982, 2000.
25. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
26. Harvey BH, Meyer CL, Gallichio VS, Manji HK. Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 36: 5-26, 2002.
27. Hasler U, Mordasini D, Bens M, Bianchi M, Cluzeaud F, Rousselot M, Vandewalle A, Feraille E, Martin PY. Long-term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J Biol Chem 277: 10379-10386, 2002.
28. Hayslett JP, Kashgarian M. A micropuncture study of the renal handling of lithium. Pflügers Arch 380: 159-163, 1979.
29. Hebert RL, Carmosino M, Saito O, Yang G, Jackson CA, Qi Z, Breyer RM, Natarajan C, Hata AN, Zhang Y, Guan Y, Breyer MD. Characterization of a rabbit kidney prostaglandin F(2alpha) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct. J Biol Chem 280: 35028-35037, 2005.
30. Hebert RL, Jacobson HR, Breyer MD. PGE2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol Renal Fluid Electrolyte Physiol 259: F318-F325, 1990.
31. Hirabayashi T, Shimizu T. Localization and regulation of cytosolic phospholipase A(2). Biochim Biophys Acta 1488: 124-138, 2000.
32. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into theinsulin-mimetic action of zinc. Biochem Biophys Res Commun 295: 102-106, 2002.
33. Kamsteeg EJ, Wormhoudt TA, Rijss JPL, van Os CH, Deen PMT. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J 18: 2394-2400, 1999.
34. Kim GH, Choi NW, Jung JY, Song JH, Lee CH, Kang CM, Knepper MA. Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2. Am J Physiol Renal Physiol 294: F702-F709, 2008.
35. Kömhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM. Localization of the prostacyclin receptor in human kidney. Kidney Int 54: 1899-1908, 1998.
36. Kortenoeven ML, Li Y, Shaw S, Gaeggeler HP, Rossier BC, Wetzels JF, Deen PM. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 76: 44-53, 2009.
37. Kortenoeven ML, van den Brand M, Wetzels JF, Deen PM. Hypotonicity- induced reduction of aquaporin-2 transcription in mpkCCD cells is independent of the tonicity responsive element, vasopressin, and cAMP. J Biol Chem 286: 13002-13010, 2011.
38. Kosten TR, Forrest JN. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 143: 1563-1568, 1986.
39. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frøkiær J, Nielsen S. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 288: F1053-F1068, 2005.
40. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 21: 771-780, 2001.
41. Laursen UH, Pihakaski-Maunsbach K, Kwon TH, Ostergaard JE, Nielsen S, Maunsbach AB. Changes of rat kidney AQP2 and Na,KATPase mRNA expression in lithium-induced nephrogenic diabetes insipidus. Nephron Exp Nephrol 97: e1-e16, 2004.
42. Li Y, Shaw S, Kamsteeg EJ, Vandewalle A, Deen PM. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 17: 1063-1072, 2006.
43. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 95: 1838-1845, 1995.
44. Matsumura Y, Uchida S, Rai T, Sasaki S, Marumo F. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 8: 861-867, 1997.
45. Meyer MC, Rastogi P, Beckett CS, McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 11: 1301-1312, 2005.
46. Nadler SP, Zimpelmann JA, Hebert RL. PGE2 inhibits water permeability at a post-cAMP site in rat terminal inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 262: F229-F235, 1992.
47. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 105: 3634-3639, 2008.
48. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013-1017, 1995.
49. Norman SJ, Poyser NL. Effects of inhibitors of arachidonic acid turnover on the production of prostaglandins by the guinea-pig uterus. J Reprod Fertil 118: 181-186, 2000.
50. Norregaard R, Jensen BL, Li C, Wang W, Knepper MA, Nielsen S, Frokiaer J. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Am J Physiol Renal Physiol 289: F322-F333, 2005.
51. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435- 439, 2003.
52. Rao R, Hao CM, Breyer MD. Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem 279: 3949-3955, 2004.
53. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 288: F642-F649, 2005.
54. Saito O, Guan Y, Qi Z, Davis LS, Komhoff M, Sugimoto Y, Narumiya S, Breyer RM, Breyer MD. Expression of the prostaglandin F receptor (FP) gene along the mouse genitourinary tract. Am J Physiol Renal Physiol 284: F1164-F1170, 2003.
55. Schumacher K, Castrop H, Strehl R, de Vries U, Minuth WW. Cyclooxygenases in the collecting duct of neonatal rabbit kidney. Cell Physiol Biochem 12: 63-74, 2002.
56. Schweer H, Watzer B, Seyberth HW. Determination of seven prostanoids in 1 ml of urine by gas chromatography-negative ion chemical ionization triple stage quadrupole mass spectrometry. J Chromatogr 652: 221-227, 1994.
57. Takahashi N, Takeuchi K, Abe T, Sugawara A, Abe K. Immunolocalization of rat thromboxane receptor in the kidney. Endocrinology 137: 5170-5173, 1996.
58. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. Long-term regulation of four renal aquaporins in rats. Am J Physiol 40: F414-F422, 1996.
59. Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 10: 666-674, 1999.
60. Tsubouchi Y, Sano H, Yamada R, Hashiramoto A, Kohno M, Kusaka Y, Kondo M. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Eur J Pharmacol 395: 255-263, 2000.
61. Walker RJ, Weggery S, Bedford JJ, McDonald FJ, Ellis G, Leader JP. Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int 67: 291-294, 2005.
62. Weinstock RS, Moses AM. Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. South Med J 83: 1475-1477, 1990.
63. Wiontzek M, Matziolis G, Schuchmann S, Gaber T, Krocker D, Duda G, Burmester GR, Perka C, Buttgereit F. Effects of dexamethasone and celecoxib on calcium homeostasis and expression of cyclooxygenase-2 mRNA in MG-63 human osteosarcoma cells. Clin Exp Rheumatol 24: 366-372, 2006.
64. Yang T, Schnermann JB, Briggs JP. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol Renal Physiol 277: F1-F9, 1999.
65. Yasui M, Zelenin SM, Celsi G, Aperia A. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 41: F443-F450, 1997.
66. Ye W, Zhang H, Hillas E, Kohan DE, Miller RL, Nelson RD, Honeggar M, Yang T. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 290: F542-F549, 2006.
67. Zook TE, Strandhoy JW. Mechanisms of the natriuretic and diuretic effects of prostaglandin F2 alpha. J Pharmacol Exp Ther 217: 674-680, 1981.